Lei Qin1,2, Xiang Li3,4, Amanda Stroiney1,5, Jinrong Qu3,4, Jeffrey Helgager6, David A Reardon7,8, Geoffrey S Young9,10. 1. Department of Imaging, Dana-Farber Cancer Institute, Boston, MA, USA. 2. Department of Radiology, Harvard Medical School, Boston, MA, USA. 3. Department of Radiology, Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, Henan, China. 4. Department of Radiology, Brigham and Women's Hospital, 75 Francis Street, Boston, MA, 02115, USA. 5. Department of Behavioral Neuroscience, College of Sciences, Northeastern University, Boston, MA, USA. 6. Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA. 7. CenterforNeuro-Oncology, Dana-Farber Cancer Institute, 44 Binney Street, Boston, MA, 02115, USA. David_Reardon@dfci.harvard.edu. 8. Department of Medicine, Harvard Medical School, Boston, MA, USA. David_Reardon@dfci.harvard.edu. 9. Department of Radiology, Harvard Medical School, Boston, MA, USA. gsyoung@partners.org. 10. Department of Radiology, Brigham and Women's Hospital, 75 Francis Street, Boston, MA, 02115, USA. gsyoung@partners.org.
Abstract
INTRODUCTION: We describe the imaging findings encountered in GBM patients receiving immune checkpoint blockade and assess the potential of quantitative MRI biomarkers to differentiate patients who derive therapeutic benefit from those who do not. METHODS: A retrospective analysis was performed on longitudinal MRIs obtained on recurrent GBM patients enrolled on clinical trials. Among 10 patients with analyzable data, bidirectional diameters were measured on contrast enhanced T1 (pGd-T1WI) and volumes of interest (VOI) representing measurable abnormality suggestive of tumor were selected on pGdT1WI (pGdT1 VOI), FLAIR-T2WI (FLAIR VOI), and ADC maps. Intermediate ADC (IADC) VOI represented voxels within the FLAIR VOI having ADC in the range of highly cellular tumor (0.7-1.1 × 10-3 mm2/s) (IADC VOI). Therapeutic benefit was determined by tissue pathology and survival on trial. IADC VOI, pGdT1 VOI, FLAIR VOI, and RANO assessment results were correlated with patient benefit. RESULTS: Five patients were deemed to have received therapeutic benefit and the other five patients did not. The average time on trial for the benefit group was 194 days, as compared to 81 days for the no benefit group. IADC VOI correlated well with the presence or absence of clinical benefit in 10 patients. Furthermore, pGd VOI, FLAIR VOI, and RANO assessment correlated less well with response. CONCLUSION: MRI reveals an initial increase in volumes of abnormal tissue with contrast enhancement, edema, and intermediate ADC suggesting hypercellularity within the first 0-6 months of immunotherapy. Subsequent stabilization and improvement in IADC VOI appear to better predict ultimate therapeutic benefit from these agents than conventional imaging.
INTRODUCTION: We describe the imaging findings encountered in GBMpatients receiving immune checkpoint blockade and assess the potential of quantitative MRI biomarkers to differentiate patients who derive therapeutic benefit from those who do not. METHODS: A retrospective analysis was performed on longitudinal MRIs obtained on recurrent GBMpatients enrolled on clinical trials. Among 10 patients with analyzable data, bidirectional diameters were measured on contrast enhanced T1 (pGd-T1WI) and volumes of interest (VOI) representing measurable abnormality suggestive of tumor were selected on pGdT1WI (pGdT1 VOI), FLAIR-T2WI (FLAIR VOI), and ADC maps. Intermediate ADC (IADC) VOI represented voxels within the FLAIR VOI having ADC in the range of highly cellular tumor (0.7-1.1 × 10-3 mm2/s) (IADC VOI). Therapeutic benefit was determined by tissue pathology and survival on trial. IADC VOI, pGdT1 VOI, FLAIR VOI, and RANO assessment results were correlated with patient benefit. RESULTS: Five patients were deemed to have received therapeutic benefit and the other five patients did not. The average time on trial for the benefit group was 194 days, as compared to 81 days for the no benefit group. IADC VOI correlated well with the presence or absence of clinical benefit in 10 patients. Furthermore, pGd VOI, FLAIR VOI, and RANO assessment correlated less well with response. CONCLUSION: MRI reveals an initial increase in volumes of abnormal tissue with contrast enhancement, edema, and intermediate ADC suggesting hypercellularity within the first 0-6 months of immunotherapy. Subsequent stabilization and improvement in IADC VOI appear to better predict ultimate therapeutic benefit from these agents than conventional imaging.
Authors: Hee Ho Chu; Seung Hong Choi; Inseon Ryoo; Soo Chin Kim; Jeong A Yeom; Hwaseon Shin; Seung Chai Jung; A Leum Lee; Tae Jin Yoon; Tae Min Kim; Se-Hoon Lee; Chul-Kee Park; Ji-Hoon Kim; Chul-Ho Sohn; Sung-Hye Park; Il Han Kim Journal: Radiology Date: 2013-10-28 Impact factor: 11.105
Authors: A Hilario; J M Sepulveda; A Perez-Nuñez; E Salvador; J M Millan; A Hernandez-Lain; V Rodriguez-Gonzalez; A Lagares; A Ramos Journal: AJNR Am J Neuroradiol Date: 2014-01-23 Impact factor: 3.825
Authors: L C Hygino da Cruz; I Rodriguez; R C Domingues; E L Gasparetto; A G Sorensen Journal: AJNR Am J Neuroradiol Date: 2011-03-10 Impact factor: 3.825
Authors: Matthew J Wieduwilt; Francisco Valles; Samar Issa; Caroline M Behler; James Hwang; Michael McDermott; Patrick Treseler; Joan O'Brien; Marc A Shuman; Soonmee Cha; Lloyd E Damon; James L Rubenstein Journal: Clin Cancer Res Date: 2012-01-06 Impact factor: 12.531
Authors: Jedd D Wolchok; Axel Hoos; Steven O'Day; Jeffrey S Weber; Omid Hamid; Celeste Lebbé; Michele Maio; Michael Binder; Oliver Bohnsack; Geoffrey Nichol; Rachel Humphrey; F Stephen Hodi Journal: Clin Cancer Res Date: 2009-11-24 Impact factor: 12.531
Authors: Peter S LaViolette; Nikolai J Mickevicius; Elizabeth J Cochran; Scott D Rand; Jennifer Connelly; Joseph A Bovi; Mark G Malkin; Wade M Mueller; Kathleen M Schmainda Journal: Neuro Oncol Date: 2014-07-24 Impact factor: 12.300
Authors: Jedd D Wolchok; Harriet Kluger; Margaret K Callahan; Michael A Postow; Naiyer A Rizvi; Alexander M Lesokhin; Neil H Segal; Charlotte E Ariyan; Ruth-Ann Gordon; Kathleen Reed; Matthew M Burke; Anne Caldwell; Stephanie A Kronenberg; Blessing U Agunwamba; Xiaoling Zhang; Israel Lowy; Hector David Inzunza; William Feely; Christine E Horak; Quan Hong; Alan J Korman; Jon M Wigginton; Ashok Gupta; Mario Sznol Journal: N Engl J Med Date: 2013-06-02 Impact factor: 91.245
Authors: David A Reardon; Prafulla C Gokhale; Sarah R Klein; Keith L Ligon; Scott J Rodig; Shakti H Ramkissoon; Kristen L Jones; Amy Saur Conway; Xiaoyun Liao; Jun Zhou; Patrick Y Wen; Annick D Van Den Abbeele; F Stephen Hodi; Lei Qin; Nancy E Kohl; Arlene H Sharpe; Glenn Dranoff; Gordon J Freeman Journal: Cancer Immunol Res Date: 2015-11-06 Impact factor: 11.151
Authors: Paula Alcaide-Leon; Tracy L Luks; Marisa Lafontaine; Janine M Lupo; Hideho Okada; Jennifer L Clarke; Javier E Villanueva-Meyer Journal: J Neurooncol Date: 2019-11-14 Impact factor: 4.130
Authors: Anna J Shangguan; Chong Sun; Bin Wang; Liang Pan; Quanhong Ma; Su Hu; Jia Yang; Aydin Eresen; Yuri Velichko; Vahid Yaghmai; Zhuoli Zhang Journal: Am J Cancer Res Date: 2019-09-01 Impact factor: 6.166
Authors: E Antonio Chiocca; Arnold B Gelb; Clark C Chen; Ganesh Rao; David A Reardon; Patrick Y Wen; Wenya Linda Bi; Pierpaolo Peruzzi; Christina Amidei; Dan Triggs; Leah Seften; Grace Park; James Grant; Kyla Truman; Jill Y Buck; Nira Hadar; Nathan Demars; John Miao; Taylor Estupinan; John Loewy; Kamal Chadha; Joseph Tringali; Laurence Cooper; Rimas V Lukas Journal: Neuro Oncol Date: 2022-06-01 Impact factor: 13.029
Authors: Catherine Coolens; Matt N Gwilliam; Paula Alcaide-Leon; Isabella Maria de Freitas Faria; Fabio Ynoe de Moraes Journal: Cancers (Basel) Date: 2021-05-23 Impact factor: 6.639